This company has been marked as potentially delisted and may not be actively trading. NASDAQ:EIGR Eiger BioPharmaceuticals (EIGR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Eiger BioPharmaceuticals Stock (NASDAQ:EIGR) Get EIGR alerts:Sign Up Key Stats Today's Range N/A50-Day Range$1.30▼$7.1752-Week Range N/AVolume137,800 shsAverage Volume103,866 shsMarket Capitalization$2.55 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California. Read More Receive EIGR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eiger BioPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EIGR Stock News HeadlinesNew Route On Eiger's North Face Will Have to WaitApril 16, 2025 | msn.comRemembering John Harlin, Eiger LegendMarch 23, 2025 | msn.comIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed professionals, retirees, and high-net-worth savers. But the wealthy aren’t just writing checks. They’re moving fast to protect capital and purchasing power using legal, IRS-compliant strategies. American Alternative Assets just released the Mar-A-Lago Accord, a free guide revealing how to reduce Q3 tax exposure and reposition wealth before it’s drained.September 16 at 2:00 AM | American Alternative (Ad)Eiger BioPharmaceuticals Inc (OTC:EIGRQ) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comEiger Biopharmaceuticals Inc (EIGRQ)September 29, 2024 | investing.comMassive Rockfall on the North Face of the EigerSeptember 8, 2024 | yahoo.comEiger BioPharmaceuticals, Inc. (EIGRQ)August 13, 2024 | finance.yahoo.com72C.SG,0P00015QPW,0 (72C.SG)August 3, 2024 | ca.finance.yahoo.comSee More Headlines EIGR Stock Analysis - Frequently Asked Questions How were Eiger BioPharmaceuticals' earnings last quarter? Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) announced its quarterly earnings results on Thursday, November, 4th. The biotechnology company reported ($19.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($17.40) by $2.10. The biotechnology company earned $3.04 million during the quarter, compared to analysts' expectations of $2.54 million. Eiger BioPharmaceuticals had a negative net margin of 590.80% and a negative trailing twelve-month return on equity of 332.49%. When did Eiger BioPharmaceuticals' stock split? Eiger BioPharmaceuticals's stock reverse split before market open on Monday, January 8th 2024.The 1-30 reverse split was announced on Monday, January 8th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of Eiger BioPharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eiger BioPharmaceuticals investors own include Enovix (ENVX), Rambus (RMBS), Ginkgo Bioworks (DNA), COMPASS Pathways (CMPS), Toast (TOST), Globant (GLOB) and Saia (SAIA). Company Calendar Last Earnings11/04/2021Today9/16/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:EIGR CIK1305253 Webwww.eigerbio.com Phone(650) 272-6138Fax650-618-1621Employees56Year Founded2008Profitability EPS (Trailing Twelve Months)($59.1592) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$96.78 million Net Margins-590.80% Pretax Margin-590.79% Return on Equity-332.49% Return on Assets-99.77% Debt Debt-to-Equity RatioN/A Current Ratio3.31 Quick Ratio3.24 Sales & Book Value Annual Sales$15.77 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$37.68 per share Price / BookN/AMiscellaneous Outstanding Shares1,480,000Free Float1,419,000Market Cap$2.55 million OptionableOptionable Beta1.83 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:EIGR) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersFanatics Hit $31B-Is This Nasdaq Next?Fanatics built an empire by owning the fan experience-scaling to a $31B valuation. But the next wave isn't abo...i2i Marketing Group, LLC | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredFree: The Crypto Summit That Could Change Your LifeWall Street’s Crypto Playbook—Revealed at This Free Event If you want to understand what's really happening...Crypto 101 Media | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eiger BioPharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eiger BioPharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.